Drug Search Results
More Filters [+]

EP-101

Alternative Names: ep-101, ep101, ep 101
Latest Update: 2018-05-09
Latest Update Note: Clinical Trial Update

Product Description

EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an investigational eFlow nebulizer (PARI Pharma GmbH).Ê (Sourced from: http://test.pharmabiz.com/news/elevation-pharma-presents-positive-golden-1-study-results-evaluating-ep-101-in-copd-patients-at-ers-congress-70972)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elevation
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EP-101

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GOLDEN-2

P2

Completed

Chronic Obstructive Pulmonary Disease

2013-04-01

2011-001810-32

P2

Completed

Chronic Obstructive Pulmonary Disease

2011-12-19

GOLDEN-1 Study

P2

Completed

Chronic Obstructive Pulmonary Disease

2011-12-01

2010-018987-17

P2

Completed

Chronic Obstructive Pulmonary Disease

2010-11-23

Recent News Events

Date

Type

Title